The North America RNA Analysis Market is experiencing robust growth due to advancements in genomics, increased investments in personalized medicine, and rising demand for transcriptomic technologies in research and diagnostics. The market, valued at USD 2,410 Million in 2025, is projected to reach USD 8,540 Million by 2035, registering a CAGR of 13.2% from 2024 to 2035.
The economic impact of tariffs on "North America RNA Analysis Market".
Market Growth Drivers
Growth in Cancer and Infectious Disease Research: Major pharmaceutical and biotechnology companies such as Illumina, Inc. have significantly invested in cancer transcriptome research using RNA analysis to uncover gene expression patterns. This investment is amplified by the ongoing need for precise biomarker identification and personalized treatment options. Rising prevalence of cancer and emerging infectious diseases in North America are propelling the demand for advanced RNA sequencing and analysis tools to facilitate early diagnosis and targeted therapies.
Technological Advancements and Product Launches: Companies like Thermo Fisher Scientific have introduced innovative RNA sequencing platforms that offer greater sensitivity, scalability, and accuracy. The release of the Ion Torrent Genexus System, for example, allows for complete RNA analysis workflows from sample to result in a single day. Such advancements have reduced turnaround time, increased throughput, and enabled widespread adoption in both clinical and research laboratories.
Market Trends
Adoption of Artificial Intelligence in RNA Data Analysis: Leading organizations such as Agilent Technologies are integrating AI-driven analytics into their RNA sequencing platforms, enabling enhanced data interpretation and automated insights. Machine learning algorithms help identify complex gene expression signatures and regulatory pathways, driving more precise and efficient bioinformatics workflows within academic and industrial research.
Expansion of Targeted RNA Sequencing: Companies like QIAGEN are developing specialized targeted RNA sequencing assays to study specific pathways or disease-relevant transcripts. This trend is boosting the precision medicine sector, where clinicians can now measure transcriptomic changes related to specific therapeutic targets, resulting in improved treatment selection and patient outcomes, particularly within oncology and rare diseases.
Market Opportunities
Expanding Use in Clinical Diagnostics: Firms such as Roche are exploring the application of RNA analysis in clinical diagnostics for the detection of genetic disorders, infectious diseases, and monitoring of treatment response, paving the way for non-invasive, high-throughput diagnostic solutions in hospitals and laboratories.
Government and Private Funding Surge: Funding initiatives by government agencies and venture capital investments are accelerating the commercialization and adoption of novel RNA sequencing technologies across academic institutions and biotech startups, encouraging further innovation and expansion in the North American market.
North America RNA Analysis Market Revenue (USD Million), 2020-2035
The revenue chart for the North America RNA Analysis Market from 2020 to 2035 illustrates a steady upward trend. Beginning at USD 900 Million in 2020, revenue surged to USD 2,410 Million by 2025, reflecting accelerated adoption of RNA-based diagnostics and research. The CAGR of 13.2% drives the market towards an estimated USD 8,540 Million by 2035. The consistent year-on-year increases highlight the impact of sustained technological innovation and rising research funding, especially within the US. The sharpest growth is projected to occur between 2029 and 2035, corresponding with the commercialization of advanced sequencing platforms and increased clinical applications.
North America RNA Analysis Market by Regions Share (%), 2025
The 2025 market share by region demonstrates the dominance of the United States, accounting for 76% of the North America RNA Analysis Market, reflecting the country’s leadership in research infrastructure and health expenditure. Canada follows with 15%, benefitting from increased genomics funding and partnerships. Mexico holds 7% share, showing gradual growth in research adoption, while smaller markets such as Puerto Rico and others contribute 1% each, mainly through academic and clinical collaborations. This regional distribution underscores the importance of robust bioscience ecosystems and government support in shaping the competitive landscape.
Recent Developments in North America RNA Analysis Market
Thermo Fisher Scientific (April 2024) announced the launch of its next-generation RNA multiplexing solutions, enabling simultaneous profiling of more than 1,000 gene targets in a single run. This advancement offers translational researchers greater flexibility and throughput, further reducing per sample costs and accelerating pathways for biomarker discovery and clinical validation.
Illumina, Inc. (March 2024) partnered with the Mayo Clinic to develop AI-powered bioinformatics pipelines for RNA-seq data, aiming to enhance precision in disease variant annotation and facilitate large-scale population genomics projects. This collaboration leverages cloud-based analytics to improve accessibility and reproducibility of RNA analysis across multiple clinical settings.
QIAGEN (February 2024) expanded its digital PCR portfolio with the launch of the QIAcuity RNA assay for rapid detection of SARS-CoV-2 variants and other respiratory pathogens. The new diagnostic tool offers faster turnaround times, high sensitivity, and multiplex capability, enabling laboratories to adapt quickly to evolving public health threats through comprehensive RNA-based surveillance.
Press Releases